Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Kringle Pharma, an Osaka University spinoff, has signed a definitive agreement granting Maruishi Pharmaceutical the exclusive rights to market its investigational vocal fold scar treatment KP-100LI in Japan, following a basic pact reached in July. Under the deal announced on…
To read the full story
Related Article
- Maruishi to Invest 300 Million Yen in Kringle Pharma
November 12, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026




